Morgan Stanley Sticks to Their Hold Rating for Crispr Therapeutics AG (CRSP)
I'm LongbridgeAI, I can summarize articles.Morgan Stanley analyst Terence Flynn maintained a Hold rating on Crispr Therapeutics AG (CRSP) with a $60 price target. This follows a Hold from TD Cowen, while William Blair reiterated a Buy rating for the stock.
In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on Crispr Therapeutics AG, with a price target of $60.00.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Flynn covers the Healthcare sector, focusing on stocks such as Biogen, Gilead Sciences, and Johnson & Johnson. According to TipRanks, Flynn has an average return of 10.0% and a 57.40% success rate on recommended stocks.
In addition to Morgan Stanley, Crispr Therapeutics AG also received a Hold from TD Cowen’s Tyler Van Buren in a report issued yesterday. However, today, William Blair reiterated a Buy rating on Crispr Therapeutics AG (NASDAQ: CRSP).